Elevated Secretion of Reactive Nitrogen and Oxygen Intermediates by Inflammatory Leukocytes in Hyperacute Experimental Autoimmune Encephalomyelitis: Enhancement by the Soluble Products of Encephalitogenic T Cells

By John D. MacMicking,*† David O. Willenborg,$ Maurice J. Weidemann,† Kirk A. Rockett,* and William B. Cowden*

From the *Division of Cell Biology, John Curtin School of Medical Research, and the †Division of Biochemistry and Molecular Biology, Faculty of Science, Australian National University; and $Neurosciences Research Unit, Royal Canberra Hospital, Canberra, ACT 2601, Australia

Summary

Perivascular lesions within the central nervous system (CNS) of rats with hyperacute experimental autoimmune encephalomyelitis (HEAE) contained large numbers of peripheral blood mononuclear cells (PBMC) and polymorphonuclear leukocytes (PMN), cells enzymatically capable of producing reactive nitrogen and oxygen intermediates (RNI and ROI), which, in excess, are mediators of tissue damage. PBMC and PMN isolated from the CNS and periphery of HEAE-affected rats secreted significantly (p < 0.01-0.0001) elevated levels of ROI and RNI compared with that of similar cell populations from pertussis- and saline-treated control animals. Coincubation of systemically derived PBMC and PMN with antigen-stimulated myelin basic protein-specific T cell lines led to further increases in ROI and RNI output of between 15.3 and 83.1%, an effect that could be largely attributed to heat-labile, soluble products released by these T cell lines. Our studies suggest a putative neuropathological role for ROI and RNI in HEAE, which may be mediated via cytokines emanating from autoreactive T lymphocytes.

Inflammatory cells, notably T cells and macrophages, are found within lesions in the central nervous system (CNS) of animals with experimental autoimmune encephalomyelitis (EAE) (1). In hyperacute EAE (HEAE), a disease variant used as a laboratory model for rapid onset multiple sclerosis and acute necrotising hemorrhagic leukoencephalopathy, significant numbers of polymorphonuclear leukocytes (PMN) are also present (2). Upon activation, both macrophages (3) and PMN (4) are major cellular sources of reactive oxygen intermediates (ROI). It is now established that these cells also secrete an additional class of effecto molecules collectively termed the reactive nitrogen intermediates (RNI), which include the highly unstable species nitric oxide (NO•), as well as its derivatives, nitrite (NO2•−) and nitrate (NO3•−) (5, 6). The strong oxidant properties of ROI and RNI provide potent antimicrobial (3, 7), parasiticidal (8), and tumoricidal (9) defense mechanisms. They are, however, also injurious to normal host tissue components (10), suggesting a possible pathogenic role in HEAE.

We report here an elevated secretion of RNI and ROI by both systemic and CNS-derived PBMC and PMN from rats during HEAE. In addition, the effects of encephalitogenic T cells or their soluble products on ROI and RNI secretion by these effector cells were examined, since it has been proposed recently that neurospecific T lymphocytes, through the action of cytokines such as TNF-α and β, and IFN-γ (11, 12), recruit and activate inflammatory cells during EAE. The priming effects of these cytokines for inducible ROI (4) and RNI (13) release are well documented.

Materials and Methods

Induction of HEAE. Under ether anesthesia, 8–10-wk-old Lewis × DA(F1) hybrid rats (180–220 g) were injected intradermally with 125 µl of guinea pig spinal cord homogenate (400 mg/ml in 9.9% NaCl) into each hind footpad along with 0.1 ml of Bordetella pertussis vaccine (10⁶ heat-killed organisms/ml) (Commonwealth Serum Labs, Melbourne, Australia) administered dorsally. Control groups received pertussis vaccine or saline alone. Clinical HEAE, which manifested 6–8 d postinoculum (p.i.), was graded according to the following criteria: 0, asymptomatic; 1, loss of distal half of tail tonicity; 2, loss of entire tail tonicity; 3, hindlimb paresis; 4, hindlimb paralysis; 5, tetraplegia; 6, death.
Cell Isolation. On day 8 p.i., PBMC and PMN from the peripheral blood of HEAE-affected rats, pertussis-immunized, and saline-treated controls were separated by Ficoll-Paque centrifugation (density 1.089 g/ml; Pharmacia Fine Chemicals AB, Uppsala, Sweden) and dextran sedimentation (T-500; Pharmacia Fine Chemicals AB) subsequent to hypertonic lysis to remove erythrocytes (14). Differential staining (Diff Quik stain; Lab Stains, Narabeen, Australia) showed that PMN fractions were 96.5 ± 1.2% pure, while PBMC fractions exhibited the following leukocyte profile: 38.7 ± 2.8% monocytes, 57.4 ± 2.4% lymphocytes, and 1.5 ± 0.8% PMN. Cell viability, as assessed by trypan blue exclusion, was consistently >95%. CNS-derived PBMC and PMN were obtained from animals that were thoroughly perfused with saline in order to remove nonadherent blood cells. Spinal cords were removed aseptically and dissected in RPMI 1640 (Gibco Laboratories, Grand Island, NY) containing 50 mg/ml type I collagenase (Sigma Chemical Co., St. Louis, MO), gently agitated (15 min, 4°C), and screened before separating by Ficoll-Paque centrifugation. Cell yields ranged from 2 to 3.5 × 10⁶ PBMC and ~5 × 10⁶ PMN per 100 mg tissue wet weight. The negligible hemoglobin content of these tissue preparations showed that the perfusion technique employed was effective.

Myelin Basic Protein-reactive T Cell Lines. Cell lines reactive to myelin basic protein (MBP-C) were generated essentially as described by Ben-Nun et al. (15). At the time of use these cells had been in continuous culture for >5 mo and had CD4⁺, CD8⁻, OX22⁻ phenotypes.

Cell Activation and Coculture Conditions. MBP-C (1.5 × 10⁶/ml) were activated by coculturing them with irradiated (2,000 rad) syngeneic thymocytes (IT) (3.5 × 10⁷/ml) for 3 d with 20 µg/ml MBP in 50 ml of DME containing 1% autologous serum, 5 × 10⁻⁵ M 2-ME, 1 mM sodium pyruvate, 2 mM l-glutamine, plus penicillin and streptomycin at 37°C in an atmosphere of 5% CO₂. Nonactivated cells were isolated from the culture by Ficoll-Paque centrifugation (14) and cultured for a further 3 d or more in DME with 10% FCS and 15% Con A-activated spleen cell supernatant as a source of IL-2. After the culture period, activated or nonactivated MBP-C were centrifuged (500 g, 5 min, 4°C) and washed twice with PBS. Subsequently, 1.5 × 10⁶ activated or nonactivated MBP-C were added to either 10⁶ PBMC for 8 h or 10⁵ PMN for 2 h, respectively, in 5.0 ml fresh DME. After coinoculation, cell suspensions were centrifuged (750 g, 10 min, 4°C), and the pellet was prepared for chemiluminescence (CL), while supernatants were set aside for assay of total RNI. Sterile filtered (0.22 µm) supernatants from MBP-C, HEAE-primed PBMC (8 h), or PMN (2 h) were used to investigate the contribution by soluble factors to ROI or RNI production, and contained <20 pg/ml endotoxin as assessed by limulus amebocyte assay (M. A. Bioproducts, Walkersville, MD).

Unstimulated Chemiluminescence. 10⁶ PBMC or 10⁵ PMN in 900 µl HBSS containing 5 mM glucose were added to dark-adapted disposable glass tubes in the presence of either 20 µl luminol (LUM) (10 mM) (Boehringer Mannheim Biochemicals, Indianapolis, IN) or 50 µl lucigenin (LUC) (5 mM) (Sigma Chemical Co.) for detection of H₂O₂/HOCI or O₂⁻, respectively (16). Cell-free suspensions served as background controls. CL was recorded over 30 min at 37°C in an unstirred system using a multichannel Lumicon luminometer (Hamilton Bonaduz AG, Bonaduz, Switzerland). Cubic spline interpolated chemiluminescence traces (ANUGraph; ANU Tech, Canberra, Australia) were integrated using an Apple Macintosh IIcx minicomputer to obtain the total counts/30 min.

NO₃⁻ and NO₂⁻ Determination. A microplate assay method (essentially as described by Rockett et al. [8]), using the Griess reagent (1% sulfanilamide plus 0.1% N-[1-naphthyl]ethylenediamine dihydrochloride [Sigma Chemical Co.] in 2.5% H₃PO₄), and a Zn/Cd/Cu catalyst to discriminate between NO₃⁻ and NO₂⁻, was used to determine total secreted RNI.

Cytokine Assays. TNF-α, IFN-γ, and IL-6 in cell culture supernatants were measured in triplicate using the following methods: (a) TNF-α by double sandwich ELISA (17); (b) IFN-γ by WEHI-279.1 proliferation assay with rRat IFN-γ (Holland Biotechnology bv, CA Leiden, The Netherlands) as the standard (18); and (c) IL-6 via a [3H]thymidine incorporation assay using the B cell hybridoma, B9 (19).

Results and Discussion

Heightened RNI and ROI Secretion from Systemic and CNS-derived PBMC and PMN during HEAE. Independent biosynthetic pathways for RNI and superoxide (O₂⁻) production have been proposed for murine monocytes/macrophages (5, 13) and human PMN (6), although this does not preclude their concomitant secretion when elicited by suitable physiological stimuli. Indeed, circulating and CNS-derived monocytes from rats clinically ill with HEAE secreted significantly more (p < 0.0001) RNI and ROI compared with pertussis-immunized and saline-treated controls (Fig. 1, a, b, and c). Levels of NO₂⁻ + NO₃⁻ in 8-h supernatants of PBMC taken from rats with neurological symptoms were some 10-fold higher (systemically derived) and 10–15-fold higher (CNS-derived) than those from pertussis or saline-treated rats (Fig. 1 a). ROI release, like RNI output, was substantially elevated in PBMC from sick animals compared with either control group as shown by unstimulated chemiluminescence. Here, increases in H₂O₂/HOCI output of ~8.0 (systemically derived) and between 9.4 and 10.2 times (CNS-derived) that of either control group were found (Fig. 1 b). Corresponding differences for O₂⁻ production (Fig. 1 c) were less pronounced, with HEAE-affected rats secreting ~4 (systemically derived) and between 3.5 and 3.8 (CNS-derived) times more than controls.

PMN isolated from HEAE-affected animals exhibited elevations in ROI output compared with PMN from control rats (H₂O₂/HOCI, >30 and >35 times, and O₂⁻ >40 and >37 times that of control animals for systemic and CNS-derived PMN, respectively; p < 0.0001 in each case) (Fig. 1 d). Cumulative RNI production by PMN (Fig. 1 d) was also greater in sick rats than controls.

Together these findings suggest that elevations in ROI and RNI output are specifically associated with the disease process, a contention supported by the following evidence. First, quantitative similarities in all three parameters for cells taken from both control groups rule out the possibility that the adjuvant, B. pertussis vaccine, alone caused increased ROI or RNI secretion. Second, to assess more accurately their state of activation in vivo, PBMC and PMN were isolated without elicitation and their CL measured without stimulation in vitro. Concurrent experiments using serum-opsonized zymosan were also undertaken, and significant differences between HEAE and control groups were found (data not shown).

In addition, the finding that the levels of RNI and ROI production by cells obtained from the peripheral circulation
versus the central nervous system of the same animal were quantitatively similar (Fig. 1) suggests that those cells entering the CNS probably do so already activated, contrary to the parenchymal activation proposed by others (20). The recent finding that NO₂ selectively contributes to the LUM-CL of PMA-stimulated macrophages (21) may under some circumstances be a limitation to the use of CL as a measure of ROI (e.g., after pretreatment with PMA [21]).

Encephalitogenic T Cells and Their Soluble Products Augment RNI and ROI Release from HEAE-primed PBMC and PMN. Autoreactive CD4⁺ T lymphocytes are not only responsible for disease induction in EAE, but are also thought to help localize and orchestrate the cellular events leading directly to CNS damage (22). The increased secretion of ROI and RNI by HEAE-primed PBMC and PMN prompted us to consider whether such secretory functions may be influenced by MBP-C. CL and RNI responses of either PBMC (10⁶ cells) or PMN (10⁵ cells) incubated for 8 and 2 h, respectively, in the presence of activated MBP-C (1.5 × 10⁴ cells) plus IT (10⁵ cells) showed that encephalitogenic T cell lines have the ability to enhance these effector functions in vitro (Fig. 2). MBP-C were only effective if first activated with antigen (Fig. 2; activated MBP-C vs. nonactivated MBP-C), and their contribution to the levels of ROI in these coincubations, like that of IT, was negligible (<6.7 × 10⁴ counts/30 min/10⁶ cells for LUM-CL, and <4.4 × 10⁴ counts/30 min/10⁵ cells for LUC-CL) (data not shown). Similarly, neither the MBP-C nor IT secreted significant amounts of RNI, typically <0.07 nmol/10⁶ cells (data not shown).

Figure 1. Individual comparison of NO₂⁻ + NO₃⁻, LUM-CL, and LUC-CL production by systemic and CNS-derived PBMC (a-c) and PMN (d-f) of HEAE (○) (n = 10) versus pertussis-immunized (●) (n = 6) and saline-treated (□) (n = 6) control rats. Cells were harvested day 8 p.i., coinciding with peak clinical severity (score: 4.71 ± 1.03). All measurements were performed in duplicate; statistical differences were measured via student's t test.

Figure 2. Effect on NO₂⁻ + NO₃⁻ or CL of systemically derived PBMC or PMN coincubated with the following: (■) nonactivated MBP-C, (●) activated MBP-C, (□) heat-inactivated MBP-C supernatants, (●) autologous supernatants. PBMC or PMN from normal donors (●) coincubated with activated MBP-C. Mean percent increases were obtained by subtracting the sum of concurrently run separate incubations, e.g. PBMC + MBP-C, from the corresponding coincubation values (PBMC + MBP-C). Cells for these experiments were taken from eight different HEAE-affected rats or four different normal rats, and measurements were performed in duplicate. Supernatants of activated MBP-C were heat inactivated at 80°C for 30 min. NO₂⁻ + NO₃⁻ enhancement was corrected for the original amount of RNI in all supernatants before coincubation with PBMC or PMN.
Table 1. Cytokine Profiles in Supernatants of MBP-C or PBMC (8 h) and PMN (2 h) Isolated from Animals with HEAE

| Supernatant | TNF-α* | IFN-γ† | IL-6‡ |
|-------------|--------|--------|-------|
| Activated MBP-C | 7.0 ± 0.24 | 26.76 ± 0.5 | 5.56 ± 0.47 |
| HIA MBP-C | 0.32 ± 0.11 | <0.4 | <0.5 |
| PBMC | 1.32 ± 0.24 | 3.72 ± 0.83 | 59.68 ± 6.73 |
| PMN | 0.72 ± 0.19 | <0.4 | 2.28 ± 0.54 |

Data are means ± sem for at least three supernatants.
* Measured by ELISA.
† Measured by bioassay.
‡ Heat inactivated.

In PBMC activated by MBP-C, O$_2^-$ production was increased 83.1% above the added values for separate MBP-C and PBMC incubations. Comparable large increases for H$_2$O$_2$/HOCl (57.5%) and NO$_2^-$ + NO$_3^-$ (42.3%) were measured (Fig. 2 a). A role for sensitized T cells in regulating PBMC in EAE has previously been demonstrated (23), with LUM-CL of EAE donors being reduced by as much as 32% after anti-CD4 antibody treatment. Coincubation of PMN with activated MBP-C also enhanced the release of O$_2^-$ by 45.1%, H$_2$O$_2$/HOCl by 59.4%, and NO$_2^-$ + NO$_3^-$ by 15.3% (Fig. 2 b) compared with the added values for MBP-C and PBMC alone.

When activated MBP-C were coincubated with PBMC or PMN from normal donors, enhancement of ROI and RNI release was much less than that seen in cells from HEAE-affected animals (Fig. 2). This may merely reflect a greater degree of priming of cells taken from sick animals, and equate, for example, with an increased level of receptor expression for cytokines, as has been shown previously in SJL and B10.PL mice with EAE (24).

The disparate effects of antigen-activated and nonactivated MBP-C on RNI and ROI production by phagocytes led us to examine whether enhancement by activated MBP-C might be due to the release of soluble mediators, since autoantigenic encounter is known to cause MBP-reactive T cell clones to produce TNF-α/β, IFN-γ, and IL-2 (11). Activated MBP-C supernatants were, on average, 75% as effective as activated MBP-C at inducing the release of RNI and ROI from either PMN (Fig. 2 a) or PMN (Fig. 2 b). This observation may be accounted for by the presence of cytokines in MBP-C supernatants, since this effect was abolished by heating at 80°C for 30 min (Fig. 2 a and b). Autologous PBMC and PMN supernatants did not induce notable increases in RNI and ROI secretion (Fig. 2 b). The cytokine profiles of these supernatants are shown in Table 1. TNF-α, and especially IFN-γ, levels were highest in the supernatants that exhibited the greatest enhancing effect (i.e., those from activated MBP-C). Low levels of these cytokines were also detected in PBMC supernatants, which had a correspondingly smaller influence on PBMC effector functions. In the remaining supernatants, TNF-α and IFN-γ were near or below the levels of assay sensitivity, and these supernatants did not alter RNI or ROI output (Fig. 2 a and b). IL-6 is reportedly elevated within the CNS during EAE (25) and capable of priming the oxidative burst in PMN and PBMC (26). This cytokine, however, was not effective at increasing the oxidative response of phagocytic cells from animals with HEAE, since its level was >10 times higher in MBP-C supernatants (59.7 U/ml; <20% enhancement) than in supernatants from activated MBP-C (5.6 U/ml; 15-75% enhancement) (Table 1).

In summary, our studies indicate a potential role for RNI and ROI in the pathogenesis of HEAE. A role for the secretory products of encephalitogenic T cells in the induction of ROI and RNI release has also been identified. Whether this relationship translates too a disease-specific mechanism is unclear, since nonencephalitogenic MBP-specific cell lines were unavailable for this study. Nevertheless, the involvement of ROI and RNI in HEAE pathology is, we believe, certainly plausible given that the CNS is not particularly well protected against oxidative stress (27). Moreover, being both a potent vasodilator (28) and neurotoxic (29), NO may contribute to the edema and motor dysfunction characteristic of HEAE.

We thank E. J. Rockett, K. M. Gray, M. M. Awburn, S. Fordham, and J. Robinson for excellent technical advice and assistance. We also thank Dr. D. Mason (University of Oxford, Oxford, England) for the mAbs against rat T cell markers, L. A. Aarden (Central Laboratory Blood Transfusion Service, Amsterdam, The Netherlands) for the B cell hybridoma B9, and Dr. A. Kelso (Walter and Eliza Hall Institute, Melbourne, Australia) for the WEHI-279.1 cell line.

This work was supported in part by grants from the National Multiple Sclerosis Society (USA) (D. O. Willenborg), the Australian Multiple Sclerosis Centre (D. O. Willenborg and W. B. Cowden), the Royal Society of London (K. A. Rockett), and Peptide Technology Ltd., Sydney (W. B. Cowden).

Address correspondence to William B. Cowden, Division of Cell Biology, John Curtin School of Medical Research, P.O. Box 334, Canberra, ACT 2601, Australia.

Received for publication 3 February 1992 and in revised form 14 April 1992.
References

1. Sobel, R.A., B.W. Blanchette, A.K. Bhan, and R.B. Colvin. 1984. The immunopathology of experimental allergic encephalomyelitis. I. Quantitative analysis of inflammatory cells in situ. J. Immunol. 132:2393.

2. Levine, S., and R. Sowinski. 1971. Allergic encephalomyelitis: a new form featuring polymorphonuclear leukocytes. Science (Wash. DC). 171:498.

3. Nathan, C.F., H.W. Murray, M.E. Weibe, and B.J. Rubin. 1987. Neutrophil activation on biological surfaces. Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. J. Clin. Invest. 80:1550.

4. Iyengar, R., D.J. Steuhr, and M.A. Marletta. 1987. Macrophage synthesis of nitrite, nitrate and N-nitrosamines: Precursors and role of the respiratory burst. Proc. Natl. Acad. Sci. USA. 84:6369.

5. Wright, C.D., A. Mulsch, R. Busse, and H. Osswald. 1989. Products of macrophage and lymphocyte. Biochem. Biophys. Res. Commun. 160:813.

6. Rockett, K.A., M.A. Awburn, W.B. Cowden, and I.A. Clark. 1992. Killing of Plasmodium falciparum in vivo by nitric oxide derivatives. Infect. Immun. 59:3280.

7. Hibbs, J.B. Jr., R.R. Taintor, and Z. Vavrin. 1987. Macrophage cytotoxicity: role for t-arginine deaminase and immonitrogen oxidation to nitrite. Science (Wash. DC). 235:473.

8. Radi, R., J.S. Beckmann, K.M. Bush, and B.A. Freeman. 1991. Peroxynitrite oxidation of sulphydryls. The cytotoxic potential of superoxide and nitric oxide. J. Biol. Chem. 266:4244.

9. Ruddle, R.H., C.M. Bergman, K.M. McGrath, E.G. Lingenheld, M.L. Grunnet, S.J. Padula, and R.B. Clark. 1990. An antibody to lymphotoxin and tumour necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1193.

10. Simmons, R.D., and D.O. Willenborg. 1990. Direct injection of cytokines into the spinal cord causes autoimmune encephalomyelitis-like inflammation. J. Neuro Sci. 100:37.

11. Ding, A.H., C.F. Nathan, and D.J. Stuehr. 1988. Release of reactive nitrogen and oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J. Immunol. 141:2407.

12. Clark, R., and S. Klebanoff. 1979. Role of myeloperoxidase-H2O2-galactose system in concanavalin A-induced tumour cell killing by human neutrophils. J. Immunol. 122:2605.

13. Ben-Nun, A., H. Wekerle, and L.R. Cohen. 1981. The rapid isolation of clonable antigen-specific F-lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol. 11:195.

14. Allen, R. 1986. Phagocytic leukocyte oxygenation activities and chemiluminescence: A kinetic approach to analysis. Methods Enzymol. 133:449.

15. Clark, I.A., J.D. MacMicking, K.M. Gray, K.A. Rockett and W.B. Cowden. 1992. Malaria mimicry with TNF: contrasts between species of murine malaria and Plasmodium falciparum. Am. J. Pathol. 140:325.

16. Reynolds, D.S., W.H. Boom, and A.K. Abbas. 1987. Inhibition of B lymphocyte activation by interferon-γ. J. Immunol. 139:767.

17. Aarden, L.A., E.R. De Groot, O.L. Schaap, and P.M. Lansdorp. 1987. Production of hybridoma growth factor by human monocytes. Eur. J. Immunol. 17:1411.

18. Huitinga, I., N. Van Rooijen, C.J.A. de Groot, B.M.J. Uitdehaag, and C.D. Dijkstra. 1990. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J. Exp. Med. 172:1025.

19. Wang, J.-F., P. Komarow, H. Sies, and H. de Groot. 1991. Contribution of nitric oxide synthase to luminal-dependent chemiluminescence generated by phorbol-ester-activated Kupffer cells. Biochem. J. 279:311.

20. Cross, A.H., B. Canella, C.F. Brosnan, and C.S. Raine. 1990. Homing to central nervous system vasculature by antigen-specific lymphocytes. I. Localisation of 125I-labeled cells during acute, chronic, and relapsing experimental allergic encephalomyelitis. Lab Invest. 63:162.

21. Hammann, K.P., S. Mainberger, J. Rosen, and H.C. Hopf. 1987. The chemiluminescence of peripheral blood mononuclear cells during acute experimental allergic encephalomyelitis. J. Neuroimmunol. 16:307.

22. Merrill, J.E., D.H. Kono, J. Clayton, G.D. Ando, D.R. Hinton, and F.M. Hofman. 1992. Inflammatory leukocytes and cytoxins in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice. Proc. Natl. Acad. Sci. USA. 89:574.

23. Giibels, K., J. Van Damme, P. Proost, W. Put, H. Carton, and A. Billiau. 1990. Interleukin 6 production in the central nervous system during experimental allergic encephalomyelitis. Eur. J. Immunol. 20:233.

24. Kharazmi, A., H. Neilson, C. Rechnitzer, and K. Bendtzen. 1989. Interleukin 6 primes human neutrophil and monocyte oxidative burst response. Immunol. Lett. 21:177.

25. Honegger, C.G., W. Krenger, and H. Langemann. 1989. Measurement of free radical scavengers in the spinal cord of rats with experimental autoimmune encephalomyelitis. Neurosci. Lett. 98:327.

26. Palmer, R.M.J., A.G. Ferridge, and S. Moncada. 1987. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (London). 327:524.

27. Dawson, V.L., T.M. Dawson, E.D. London, D.S. Bredt, and S.H. Snyder. 1991. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Natl. Acad. Sci. USA. 88:6368.